Maccura Biotechnology Co Ltd
SZSE:300463
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.9), the stock would be worth ¥10.41 (1% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.9 | ¥10.49 |
0%
|
| 3-Year Average | 2.9 | ¥10.41 |
-1%
|
| 5-Year Average | 3 | ¥10.69 |
+2%
|
| Industry Average | 6.1 | ¥22.02 |
+110%
|
| Country Average | 3.3 | ¥11.82 |
+13%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥6.5B
|
/ |
Oct 2025
¥2.2B
|
= |
|
|
¥6.5B
|
/ |
Dec 2025
¥2.4B
|
= |
|
|
¥6.5B
|
/ |
Dec 2026
¥2.5B
|
= |
|
|
¥6.5B
|
/ |
Dec 2027
¥2.6B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
M
|
Maccura Biotechnology Co Ltd
SZSE:300463
|
6.3B CNY | 2.9 | -54 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 328.4 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 4.7 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 5.5 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 6.4 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 5.5 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 4.8 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 9.6 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 2.4 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 6.9 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Maccura Biotechnology Co Ltd
Glance View
Maccura Biotechnology Co. Ltd., rooted in Chengdu, China, has grown from a nascent enterprise into a significant player in the global in vitro diagnostics (IVD) industry. The company was established with a clear vision: to innovate and provide reliable diagnostic solutions. Over the years, Maccura has carved a niche by focusing on the development, manufacturing, and distribution of a comprehensive range of diagnostic products, including reagents, analyzers, and control materials. These products are crucial for diagnosing various conditions, from infectious diseases to chronic illnesses, allowing healthcare professionals to make informed decisions. Maccura's reputation is built on its commitment to rigorous research and development, ensuring its offerings meet an international standard of quality. The financial blueprint of Maccura lies predominantly in its ability to develop proprietary technology and leverage strategic partnerships across the globe. They generate revenue through the sale of diagnostic instruments and consumables, which are essential components that need frequent replenishing by hospitals and laboratories, creating a steady stream of income. Furthermore, Maccura continually invests in expanding its product lineup and enhancing production capabilities. By tapping into the rising demand for accurate and efficient diagnostic solutions, especially in the wake of global health challenges, Maccura has effectively positioned itself to capture a substantial market share both domestically and internationally. Through a well-orchestrated blend of innovation, quality assurance, and strategic growth initiatives, the company continues to solidify its status as a cornerstone in the healthcare diagnostics realm.